Enovis Corporation will present at the J.P. Morgan Healthcare Conference on January 12, 2026, with a live webcast available.
Quiver AI Summary
Enovis Corporation, a medical technology company, announced that its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST. The company will provide a live audio webcast of the presentation, accessible through its website along with accompanying slides and a replay. Enovis focuses on developing innovative healthcare solutions to improve patient outcomes and enhance operational efficiency for healthcare professionals. The company emphasizes its commitment to advancing medical care and encourages stakeholders to stay informed through its Investor Relations website, where material information is regularly posted.
Potential Positives
- Enovis Corporation is actively engaging with investors at a prominent industry event, enhancing its visibility and fostering relationships within the healthcare investment community.
- The live audio webcast and presentation availability demonstrate Enovis's commitment to transparency and accessibility of information for its investors.
- This participation at the J.P. Morgan Healthcare Conference highlights Enovis's position as an innovation-driven medical technology growth company, potentially attracting new investors and partners.
Potential Negatives
- The announcement lacks specific details about the company's current financial performance or forecasts, which may lead to investor uncertainty.
- The press release does not mention any new product launches or innovations that could excite investors, potentially indicating a lack of recent progress or developments.
- The communication method for material information relies heavily on the company's website, which may not be accessible to all investors in real-time, posing a risk of information asymmetry.
FAQ
What is the date and time of the Enovis presentation at the conference?
The Enovis presentation is scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST).
Where can I access the live audio webcast of the presentation?
The live audio webcast will be available on Enovis's website at www.enovis.com under Events and Presentations.
What does Enovis Corporation specialize in?
Enovis Corporation specializes in developing innovative medical technology solutions that improve patient outcomes and enhance quality of life.
How can I find more information about Enovis's investor relations?
You can find more information about Enovis's investor relations at their dedicated site: ir.enovis.com.
Who should I contact for more press information regarding Enovis?
You can contact Kyle Rose, Vice President of Investor Relations, via email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ENOV Insider Trading Activity
$ENOV insiders have traded $ENOV stock on the open market 9 times in the past 6 months. Of those trades, 5 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ENOV stock by insiders over the last 6 months:
- DANIEL A PRYOR has made 1 purchase buying 10,000 shares for an estimated $289,000 and 4 sales selling 1,665 shares for an estimated $45,297.
- DAMIEN MCDONALD (Chief Executive Officer) purchased 6,457 shares for an estimated $199,973
- BRADLEY J TANDY (SVP and Chief Legal Officer) purchased 3,200 shares for an estimated $100,512
- JOHN KLECKNER (Principal Accounting Officer) purchased 2,468 shares for an estimated $74,829
- PHILLIP BENJAMIN (BEN) BERRY (SVP, Chief Financial Officer) purchased 2,500 shares for an estimated $74,275
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ENOV Revenue
$ENOV had revenues of $548.9M in Q3 2025. This is an increase of 8.65% from the same period in the prior year.
You can track ENOV financials on Quiver Quantitative's ENOV stock page.
$ENOV Hedge Fund Activity
We have seen 145 institutional investors add shares of $ENOV stock to their portfolio, and 157 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 2,750,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $83,435,000
- ROYCE & ASSOCIATES LP removed 1,697,683 shares (-70.2%) from their portfolio in Q3 2025, for an estimated $51,507,702
- FMR LLC added 1,258,457 shares (+19756.0%) to their portfolio in Q3 2025, for an estimated $38,181,585
- NUVEEN, LLC added 807,991 shares (+252.0%) to their portfolio in Q3 2025, for an estimated $24,514,446
- DIAMOND HILL CAPITAL MANAGEMENT INC removed 781,393 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $23,707,463
- TRIBUTARY CAPITAL MANAGEMENT, LLC added 551,613 shares (+91.5%) to their portfolio in Q3 2025, for an estimated $16,735,938
- AQR CAPITAL MANAGEMENT LLC removed 463,681 shares (-93.0%) from their portfolio in Q3 2025, for an estimated $14,068,081
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ENOV Analyst Ratings
Wall Street analysts have issued reports on $ENOV in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/06/2026
- Freedom Capital Markets issued a "Buy" rating on 12/17/2025
- Wells Fargo issued a "Overweight" rating on 11/07/2025
- UBS issued a "Buy" rating on 08/08/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
- Needham issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $ENOV, check out Quiver Quantitative's $ENOV forecast page.
$ENOV Price Targets
Multiple analysts have issued price targets for $ENOV recently. We have seen 6 analysts offer price targets for $ENOV in the last 6 months, with a median target of $47.0.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $41.0 on 01/06/2026
- Keith Hinton from Freedom Capital Markets set a target price of $45.0 on 12/17/2025
- Caitlin Cronin from Canaccord Genuity set a target price of $50.0 on 12/17/2025
- Vik Chopra from Wells Fargo set a target price of $42.0 on 11/07/2025
- Danielle Antalffy from UBS set a target price of $57.0 on 08/08/2025
- Mike Matson from Needham set a target price of $49.0 on 08/07/2025
Full Release
Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12 th , 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website ( www.enovis.com ) at Events and Presentations.
About Enovis
Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
Contact:
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
[email protected]
